Ashvattha Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced that Jeffrey Cleland, Ph.D., chairman, chief executive officer and president, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference. The presentation by Dr. Cleland will include an overview of the company and provide an update